American journal of nuclear medicine and molecular imaging最新文献

筛选
英文 中文
In vitro evaluation of PET radiotracers for imaging synaptic density, the acetylcholine transporter, AMPA-tarp-γ8 and muscarinic M4 receptors in Alzheimer's disease. 用于阿尔茨海默病突触密度、乙酰胆碱转运体、AMPA-tarp-γ8 和毒蕈碱 M4 受体成像的 PET 放射性同位素体外评估。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Faustine d'Orchymont, Andrea Narvaez, Roger Raymond, Pallavi Sachdev, Arnaud Charil, Stephen Krause, Neil Vasdev
{"title":"In vitro evaluation of PET radiotracers for imaging synaptic density, the acetylcholine transporter, AMPA-tarp-γ8 and muscarinic M4 receptors in Alzheimer's disease.","authors":"Faustine d'Orchymont, Andrea Narvaez, Roger Raymond, Pallavi Sachdev, Arnaud Charil, Stephen Krause, Neil Vasdev","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Several therapeutics and biomarkers that target Alzheimer's disease (AD) are under development. Our clinical positron emission tomography (PET) research programs are interested in six radiopharmaceuticals to image patients with AD and related dementias, specifically [<sup>11</sup>C]UCB-J and [<sup>18</sup>F]SynVesT-1 for synaptic vesicle glycoprotein 2A as a marker of synaptic density, two vesicular acetylcholine transporter PET radiotracers: [<sup>18</sup>F]FEOBV and [<sup>18</sup>F]VAT, as well as the transmembrane AMPA receptor regulatory protein (TARP)-γ8 tracer, [<sup>18</sup>F]JNJ-64511070, and the muscarinic acetylcholine receptor (mAChR) M4 tracer [<sup>11</sup>C]MK-6884. The goal of this study was to compare all six radiotracers (labeled with tritium or <sup>18</sup>F) by measuring their density variability in pathologically diagnosed cases of AD, mild cognitive impairment (MCI) and normal healthy volunteer (NHV) human brains, using thin-section <i>in vitro</i> autoradiography (ARG). Region of interest analysis was used to quantify radioligand binding density and determine whether the radioligands provide a signal-to-noise ratio optimal for showing changes in binding. Our preliminary study confirmed that all six radiotracers show specific binding in MCI and AD. An expected decrease in their respective target density in human AD hippocampus tissues compared to NHV was observed with [<sup>3</sup>H]UCB-J, [<sup>3</sup>H]SynVesT-1, [<sup>3</sup>H]JNJ-64511070, and [<sup>3</sup>H]MK-6884. This preliminary study will be used to guide human PET imaging of SV2A, TARP-γ8 and the mAChR M4 subtype for imaging in AD and related dementias.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis. 聚(ADP-核糖)聚合酶(PARP)靶向 PET 成像在非肿瘤学中的应用:非酒精性脂肪性肝炎临床前模型的试验研究。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Troels E Jeppesen, Tuo Shao, Jiahui Chen, Jimmy S Patel, Xin Zhou, Andreas Kjaer, Steven H Liang
{"title":"Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis.","authors":"Troels E Jeppesen, Tuo Shao, Jiahui Chen, Jimmy S Patel, Xin Zhou, Andreas Kjaer, Steven H Liang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Poly(ADP-ribose) polymerase (PARP) activation often indicates a disruptive signal to lipid metabolism, the physiological alteration of which may be implicated in the development of non-alcoholic fatty liver disease. The objective of this study was to evaluate the capability of [<sup>68</sup>Ga]DOTA-PARPi PET to detect hepatic PARP expression in a non-alcoholic steatohepatitis (NASH) mouse model. In this study, male C57BL/6 mice were subjected to a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) for a 12-week period to establish preclinical NASH models. [<sup>68</sup>Ga]DOTA-PARPi PET imaging of the liver was conducted at the 12-week mark after CDAHFD feeding. Comprehensive histopathological analysis, covering hepatic steatosis, inflammation, fibrosis, along with blood biochemistry, was performed in both NASH models and control groups. Despite the induction of severe inflammation, steatosis and fibrosis in the liver of mice with the CDAHFD-NASH model, PET imaging of NASH with [<sup>68</sup>Ga]-DOTA-PARPi did not reveal a significantly higher uptake in NASH models compared to the control. This underscores the necessity for further development of new chelator-based PARP1 tracers with high binding affinity to enable the visualization of PARP1 changes in NASH pathology.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case report: diagnosis and treatment of advanced high-grade serous ovarian carcinoma aided by 68Ga-FAPI PET/MR scan. 病例报告:68Ga-FAPI PET/MR 扫描辅助诊断和治疗晚期高级别浆液性卵巢癌。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Mengna Zhu, Si Sun, Lin Huang, Mengqing Chen, Jing Cai, Zehua Wang, Liqiong Cai
{"title":"Case report: diagnosis and treatment of advanced high-grade serous ovarian carcinoma aided by <sup>68</sup>Ga-FAPI PET/MR scan.","authors":"Mengna Zhu, Si Sun, Lin Huang, Mengqing Chen, Jing Cai, Zehua Wang, Liqiong Cai","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>High-grade serous ovarian cancer (HGSOC) is the most common type of epithelial ovarian cancer with insidious onset, rapid growth, and invasive spread. Here, we reported the diagnosis and treatment of a 53-year-old patient with a history of hysterectomy aided by the <sup>68</sup>Ga-FAPI PET/MR scan. The patient was first presented to the local hospital with a lump on the left side of the neck with a biopsy suggesting metastatic cancer. Pelvic ultrasonography revealed two irregular masses. After admission, tumor markers, pathology consultation of the biopsy, and the <sup>68</sup>Ga-FAPI PET/MR scan were administered. The biopsy of the lump suggested poorly differentiated adenocarcinoma and CA125 was elevated at 530.6 U/ml. The <sup>68</sup>Ga-FAPI PET/MR scan showed several abnormal lymph nodes and two soft tissue masses with borders of dispersed restriction displaying internally uneven signals depicted by slightly elongated T1 and T2 signals within the pelvic cavity suggesting that pelvic mass could be the primary lesion. The patient received cytoreductive surgery including bilateral adnexectomy, omentectomy, and appendectomy. Post-surgical pathology suggested left and right HGSOC with left fallopian tube invasion. The patient completed six courses of first-line chemotherapy and remained progression-free for 14 months up to date. To conclude, <sup>68</sup>Ga-FAPI PET/MR aids in primary tumor determination and tumor burden assessment and provides a guide for the management of late-stage HGSOC patients.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro evaluation of PET radiotracers reflecting multidimensionality of Alzheimer's disease: building more roadmaps for clinical translation. 对反映阿尔茨海默病多维性的 PET 放射性同位素进行体外评估:为临床转化绘制更多路线图。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Yingfang He, Fang Xie
{"title":"In vitro evaluation of PET radiotracers reflecting multidimensionality of Alzheimer's disease: building more roadmaps for clinical translation.","authors":"Yingfang He, Fang Xie","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the current issue of American Journal of Nuclear Medicine and Molecular Imaging, Vasdev et al. presented a work entitled \"In Vitro Evaluation of PET Radiotracers for Imaging Synaptic Density, the Acetylcholine Transporter, AMPA-tarp-γ8 and Muscarinic M4 receptors in Alzheimer's disease\". In which, in vitro autoradiography studies using radioligands were employed as a valuable tool to gain more insights for potential clinical translation. In this invited perspective, we would like to briefly introduce the current state of AD diagnosis, especially PET imaging on synapse, and highlight the advances of PET imaging in pre-clinic and clinic that might assist on precise therapy in the future.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of factors affecting CT attenuation and glucose metabolism of bone marrow as seen on PET/CT scans. 研究 PET/CT 扫描显示的影响 CT 衰减和骨髓葡萄糖代谢的因素。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Shiro Ishii, Ryo Yamakuni, Shigeyasu Sugawara, Junko Hara, Yoshiki Endo, Hirotoshi Hotsumi, Mahori Hiruta, Honami Kobiyama, Yuki Yaginuma, Kenji Fukushima, Hiroshi Ito
{"title":"Investigation of factors affecting CT attenuation and glucose metabolism of bone marrow as seen on PET/CT scans.","authors":"Shiro Ishii, Ryo Yamakuni, Shigeyasu Sugawara, Junko Hara, Yoshiki Endo, Hirotoshi Hotsumi, Mahori Hiruta, Honami Kobiyama, Yuki Yaginuma, Kenji Fukushima, Hiroshi Ito","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of this study is to determine the factors affecting the CT attenuation of bone marrow, and its correlation with <sup>18</sup>F-FDG uptake. The mean standardized uptake value (SUV) of vertebral bone marrow (Vertebral-SUV) and femoral bone marrow (Femoral-SUV) as well as CT number of bone marrow (BM-CT number) were measured in 243 patients who had undergone <sup>18</sup>F-FDG PET/CT. The correlations among BM-CT number, Femoral-SUV, and Vertebral-SUV were investigated. The relationships of Femoral-SUV, Vertebral-SUV, and BM-CT number with blood parameters, age, blood sugar, and body weight were analyzed by correlation and multi-regression analyses. The Mann-Whitney U test and chi-square test and Binomial logistic analysis were used to examine the relationships between high BM-CT number (≥ 0 HU) and the above parameters. Significant correlations were observed between: BM-CT number and Femoral-SUV (r = 0.73, P < 0.01); Vertebral-SUV and Femoral-SUV (r = 0.78, P < 0.01); and BM-CT number and Vertebral-SUV (r = 0.52, P < 0.01). BM-CT number was correlated with patients' age in both univariable (r = -0.27) and multivariable analyses (β = -0.20). Positive BM-CT number correlated with WBC in both univariable (P = 0.04) and multivariable (P < 0.01) analyses. Bone marrow glucose metabolism had a tendency to decrease with age, was increased in patients with elevated CRP. In conclusion, CT attenuation of bone marrow correlated well with bone marrow metabolism and also tended to decrease with age. High bone marrow attenuation (≥ 0 HU) could predict elevated serum WBC.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab. 用 64Cu 标记的 Durvalumab 对肿瘤 PD-L1 表达进行无创 PET 成像。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Sara Malih, Wilson Lin, Zhongmin Tang, Molly C DeLuca, Jonathan W Engle, Behrouz Alirezapour, Weibo Cai, Mohammad J Rasaee
{"title":"Noninvasive PET imaging of tumor PD-L1 expression with <sup>64</sup>Cu-labeled Durvalumab.","authors":"Sara Malih, Wilson Lin, Zhongmin Tang, Molly C DeLuca, Jonathan W Engle, Behrouz Alirezapour, Weibo Cai, Mohammad J Rasaee","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Breast cancer (BrCa) ranks as the most prevalent malignant neoplasm affecting women worldwide. The expression of programmed death-ligand 1 (PD-L1) in BrCa has recently emerged as a biomarker for immunotherapy response, but traditional immunohistochemistry (IHC)-based methods are hindered by spatial and temporal heterogeneity. Noninvasive and quantitative PD-L1 imaging using appropriate radiotracers can serve to determine PD-L1 expression in tumors. This study aims to demonstrate the viability of PET imaging with <sup>64</sup>Cu-labeled Durvalumab (abbreviated as Durva) to assess PD-L1 expression using a murine xenograft model of breast cancer. Durvalumab, a human IgG1 monoclonal antibody against PD-L1, was assessed for specificity <i>in vitro</i> in two cancer cell lines (MDA-MB-231 triple-negative breast cancer cell line and AsPC-1 pancreatic cancer cell line) with positive and negative PD-L1 expression by flow cytometry. Next, we performed the <i>in vivo</i> evaluation of <sup>64</sup>Cu-NOTA-Durva in murine models of human breast cancer by PET imaging and <i>ex vivo</i> biodistribution. Additionally, mice bearing AsPC-1 tumors were employed as a negative control. Tumor uptake was quantified based on a 3D region-of-interest (ROI) analysis of the PET images and <i>ex vivo biodistribution</i> measurements, and the results were compared against conventional IHC testing. The radiotracer uptake was evident in MDA-MB-231 tumors and showed minimal nonspecific binding, corroborating IHC-derived results. The results of the biodistribution showed that the MDA-MB-231 tumor uptake of <sup>64</sup>Cu-NOTA-Durva was much higher than <sup>64</sup>Cu-NOTA-IgG (a nonspecific radiolabeled IgG). In Conclusion, <sup>64</sup>Cu-labeled Durvalumab PET/CT imaging offers a promising, noninvasive approach to evaluate tumor PD-L1 expression.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two decades of [11C]PiB synthesis, 2003-2023: a review. 2003-2023 年[11C]PiB 合成二十年:回顾。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Paul Josef Myburgh, Kiran Kumar Solingapuram Sai
{"title":"Two decades of [<sup>11</sup>C]PiB synthesis, 2003-2023: a review.","authors":"Paul Josef Myburgh, Kiran Kumar Solingapuram Sai","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Because carbon-11 (<sup>11</sup>C) radiotracers cannot be shipped over long distances, their use in routine positron emission tomography (PET) studies is dependent on the production capabilities of individual radiochemistry laboratories. Since 2003, <sup>11</sup>C-labeled Pittsburgh compound B ([<sup>11</sup>C]PiB) has been the gold standard PET radiotracer for <i>in vivo</i> imaging of amyloid β (Aβ) plaques. For more than two decades, researchers have been working to develop faster, higher-yielding, more robust, and optimized production methods with higher radiochemical yields for various imaging applications. This review evaluates progress in [<sup>11</sup>C]PiB radiochemistry. An introductory overview assesses how it has been applied in clinical neurologic imaging research. We examine the varying approaches reported for radiolabeling, purification, extraction, and formulation. Further considerations for QC methods, regulatory considerations, and optimizations were also discussed.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer. 分子成像揭示肿瘤细胞和肿瘤基质的异质性进展:FDG PET 和 FAPI PET 在诊断 PSMA 阴性进展期前列腺癌骨转移中的应用。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Lizhi Zhu, Peng Chen, Zhongqiu Guo, Fangdu Li, Xiu Luo, Xia Du, Liying Zhang, Changjing Zuo, Xiao Li
{"title":"Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer.","authors":"Lizhi Zhu, Peng Chen, Zhongqiu Guo, Fangdu Li, Xiu Luo, Xia Du, Liying Zhang, Changjing Zuo, Xiao Li","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tumors are often with complex and heterogeneous biological processes, such as glycometabolism and fibrosis, which are the main biochemical pathways that determine therapeutic effects. Specifically, this study aims to assess the diagnosing performance of <sup>18</sup>F-FDG and <sup>68</sup>Ga-FAPI-04 PET for different stages of progressive bone metastases with PSMA-negative pathology. Bone metastatic mouse model of prostate cancer was constructed via intra-bone injection of PSMA-negative prostate cancer PC3 cells. Cellular uptakes of <sup>18</sup>F-FDG and <sup>68</sup>Ga-FAPI-04 were separately performed on PC3, NIH-3T3 (FAP-positive) and a mixture. <sup>68</sup>Ga-PSMA-11, <sup>18</sup>F-FDG and <sup>68</sup>Ga-FAPI-04 PET/CT imaging were performed at 2, 4 weeks after tumor cell transplantation. Furthermore, PSMA and FAP expression in bone metastases were assessed by immunohistochemistry, and then compared with the imageological findings. On the cellular level, the independent tracer uptake on the basis of glycometabolism and fibrosis was observed. For animal imaging, <sup>68</sup>Ga-PSMA-11 imaging showed weak or absent tracer uptake in PSMA-negative bone metastatic lesions. In contrast, <sup>68</sup>Ga-FAPI-04 PET of bone metastases had a higher uptake and tumor-to-muscle (T/M) ratio than <sup>18</sup>F-FDG PET that was relative steady during the observation, but T/M ratio of fibrosis gradually decreased with increasing tumor growth, which ranged from 5.11 ± 1.26 at 2 weeks to 3.54 ± 0.23 at 4 weeks, revealing the delayed formation of tumor stroma in rapid proliferation. In addition, PET imaging results were corroborated by immunohistochemical assessment. In conclusion, molecular imaging approach revealed the heterogeneous progression of tumor cells and tumor stroma of bone metastasis of prostate cancer, and further confirming the necessity of multi-molecular imaging in cancer imaging.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unexpected 99mTc-pertechnetate avidity of lymph node metastases predicts better response to radioiodine therapy in differentiated thyroid cancer patients with lymph node metastases. 有淋巴结转移的分化型甲状腺癌患者淋巴结转移灶的99m锝-过硫酸盐嗜性可预示对放射性碘治疗的更好反应。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Jie Liu, Xin Li, Linfa Li, Yuhua Yin, Hu Cai, Heqing Yi
{"title":"Unexpected <sup>99m</sup>Tc-pertechnetate avidity of lymph node metastases predicts better response to radioiodine therapy in differentiated thyroid cancer patients with lymph node metastases.","authors":"Jie Liu, Xin Li, Linfa Li, Yuhua Yin, Hu Cai, Heqing Yi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the value of <sup>99m</sup>Tc-pertechnetate scan in postoperative differentiated thyroid cancer (DTC) patients with lymph node (LN) metastases (LNM) uptake <sup>99m</sup>Tc-pertechnetate, especially the predictive value to their response to radioiodine-131 (<sup>131</sup>I) therapy.</p><p><strong>Methods: </strong>This retrospective study collected 752 patients with DTC and LNM treated at Zhejiang Cancer Hospital between May 2012 and December 2017. Depending on the ability of LNM uptake <sup>99m</sup>Tc-pertechnetate, the patients were grouped as the <sup>99m</sup>Tc-pertechnetate-avid (n=88) vs. <sup>99m</sup>Tc-pertechnetate-non-avid (n=664) groups. And Propensity score matching (PSM) was performed at a 1:4 ratio to reduce confounding bias.</p><p><strong>Results: </strong>In the PSM analysis, the 1:4 matched cohort comprised 752 patients (88 with <sup>99m</sup>Tc-pertechnetate-avid LNM, 664 with <sup>99m</sup>Tc-pertechnetate-non-avid LNM). Patients' age, initial <sup>131</sup>I activity and frequency of iodine therapy were included as covariates. After PSM analysis, 363 patients (<sup>99m</sup>Tc-pertechnetate-avid group, n=83; <sup>99m</sup>Tc-pertechnetate-non-avid group, n=280) were successfully matched. Among the 363 PSM-matched patients, 48/83 (57.8%) in the <sup>99m</sup>Tc-pertechnetate-avid group and 158/280 (56.4%) in the <sup>99m</sup>Tc-pertechnetate-non-avid group had two or more <sup>131</sup>I treatments. The nsTg and the percentage of changes in ssTg between the <sup>99m</sup>Tc-pertechnetate-avid and <sup>99m</sup>Tc-pertechnetate-non-avid groups were significantly different ([0.05 (0.04 to 0.90) vs. 0.40 (0.04 to 4.92), <i>p</i>=0.018] and [-88% (-98%, -50%) vs. -66% (-86%, -30%), <i>p</i> < 0.001], respectively). No significant differences were observed between the two groups in the other parameters (age, pathological type, distant metastasis, follow-up time, AJCC TNM stage, initial <sup>131</sup>I treatment activity, and <sup>131</sup>I treatment frequency) after PSM (all <i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>In patients with DTC and LNM, LNM uptake of <sup>99m</sup>Tc-pertechnetate is a rare phenomenon. Patients with <sup>99m</sup>Tc-pertechnetate-avid LNMs were more likely to benefit from <sup>131</sup>I therapy, even after adjustment for age, <sup>131</sup>I treatment frequency, and initial <sup>131</sup>I activity.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma: a comprehensive evaluation method. 18F-FDG PET/CT 在结外自然杀伤/T 细胞淋巴瘤中的应用:一种综合评估方法。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2023-12-25 eCollection Date: 2023-01-01
Xiaoyue Zhang, Wenpeng Huang, Yongkang Qiu, Zhao Chen, Lele Song, Qi Yang, Lei Kang
{"title":"<sup>18</sup>F-FDG PET/CT in extranodal natural killer/T-cell lymphoma: a comprehensive evaluation method.","authors":"Xiaoyue Zhang, Wenpeng Huang, Yongkang Qiu, Zhao Chen, Lele Song, Qi Yang, Lei Kang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Extranodal NK/T-cell lymphoma (ENKTL) is an uncommon subtype of non-Hodgkin's lymphoma that is closely related to Epstein-Barr virus (EBV) infection. ENKTL exhibits distinctive clinicopathological features among lymphomas and has poor overall survival in the absence of effective treatment. The timely and accurate diagnosis of ENKTL is crucial for effective treatment and a positive prognosis. <sup>18</sup>F-Fluorodeoxyglucose-positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) has emerged as an invaluable diagnostic modality for staging, curative effect evaluation, and prognosis analysis in ENKTL. We herein provide a comprehensive overview of the advances in the application of <sup>18</sup>F-FDG PET/CT in patients with ENKTL.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信